|
| 3.__Immunity; presumption of good faith.__A pharmacist or person | acting at the direction of a pharmacist who in good faith and | pursuant to subsection 2 refuses to fill any prescription, dispense | any drug or sell any targeted methamphetamine precursor or who | makes a report to a law enforcement agency is immune from any civil | liability that might otherwise result from that action, including, | but not limited to, any civil liability that might otherwise arise | under state or local laws or rules regarding confidentiality of | information. In a proceeding regarding immunity from liability, | there is a rebuttable presumption of good faith. |
|
| | 4.__Record keeping.__With regard to purchases of targeted | methamphetamine precursors, a pharmacy may keep a log of | information about the purchaser, which may include name, date of | birth, address and amount of targeted methamphetamine precursors | purchased. |
|
| | 5.__Rulemaking. The Director of the Office of Substance Abuse | within the Department of Health and Human Services may adopt | rules to implement this subsection.__Rules adopted pursuant to | this subsection are major substantive rules as defined in Title | 5, chapter 375, subchapter 2-A. |
|
| A.__If the Director of the Maine Drug Enforcement Agency | within the Department of Public Safety finds that the ease | of availability of liquid, liquid-filled capsule or glycerin | matrix forms of products containing ephedrine, | pseudoephedrine or phenylpropanolamine or their salts, | isomers or salts of isomers, either alone or in combination | with other ingredients, referred to in this paragraph as | "products," is a threat to the public health, safety and | welfare, then the Director of the Maine Drug Enforcement | Agency shall notify the Director of the Office of Substance | Abuse.__The Director of the Office of Substance Abuse shall | consult with the joint standing committee of the Legislature | having jurisdiction over health and human services matters, | providing the reasons for undertaking rulemaking, and may, | after consultation, adopt rules designating the products as | targeted methamphetamine precursors pursuant to section | 13702, subsection 25-B, paragraph B. |
|
| B. If the Director of the Maine Drug Enforcement Agency finds | that sales of targeted methamphetamine precursors that are made | without verifying the identity of the purchaser pose a threat to | public health, safety and welfare, then the Director of the Maine | Drug Enforcement Agency shall notify the Director of the Office | of Substance Abuse.__The Director of the Office of Substance | Abuse shall consult with the |
|
|